Rhythm Pharmaceuticals, Inc.
RYTM
$93.72
$2.412.64%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 58.67% | 45.83% | 54.92% | 53.55% | 48.88% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 58.67% | 45.83% | 54.92% | 53.55% | 48.88% |
| Cost of Revenue | 61.86% | 45.80% | 44.18% | 47.43% | 32.95% |
| Gross Profit | 58.30% | 45.83% | 56.30% | 54.32% | 50.98% |
| SG&A Expenses | 47.27% | 35.09% | 26.74% | 18.63% | 17.07% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 33.94% | 25.90% | 26.22% | 21.37% | 14.10% |
| Operating Income | -14.34% | -10.92% | -7.56% | -2.46% | 3.73% |
| Income Before Tax | -19.67% | 24.66% | 25.70% | 29.06% | 38.26% |
| Income Tax Expenses | 669.60% | 44.06% | -30.59% | -101.27% | -85.53% |
| Earnings from Continuing Operations | -20.15% | 24.57% | 25.72% | 29.44% | 38.40% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -20.15% | 24.57% | 25.72% | 29.44% | 38.40% |
| EBIT | -14.34% | -10.92% | -7.56% | -2.46% | 3.73% |
| EBITDA | -14.66% | -11.16% | -7.72% | -2.55% | 3.67% |
| EPS Basic | -11.46% | 28.70% | 28.47% | 30.88% | 39.30% |
| Normalized Basic EPS | -5.98% | -4.12% | -4.06% | -0.03% | 6.93% |
| EPS Diluted | -11.46% | 28.70% | 28.47% | 30.88% | 39.30% |
| Normalized Diluted EPS | -5.98% | -4.12% | -4.06% | -0.03% | 6.93% |
| Average Basic Shares Outstanding | 7.25% | 6.52% | 5.39% | 4.75% | 5.46% |
| Average Diluted Shares Outstanding | 7.25% | 6.52% | 5.39% | 4.75% | 5.46% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |